Home/Filings/4/0001209191-18-056052
4//SEC Filing

TUFTS LINDA 4

Accession 0001209191-18-056052

CIK 0001169245other

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 4:20 PM ET

Size

85.5 KB

Accession

0001209191-18-056052

Insider Transaction Report

Form 4
Period: 2018-10-22
TUFTS LINDA
Director
Transactions
  • Exercise/Conversion

    Series C-1 Preferred Stock

    2018-10-22$0.12/sh+9,847$1,18247,377 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (9,847 underlying)
  • Exercise/Conversion

    Warrants to Purchase Series C-1 Preferred Stock

    2018-10-229910 total(indirect: By FSV II, LP)
    Exercise: $0.12Series C-1 Preferred Stock (991 underlying)
  • Purchase

    Common Stock

    2018-10-22$5.00/sh+1,277$6,38559,429 total(indirect: By FSV II, LP)
  • Purchase

    Common Stock

    2018-10-22$5.00/sh+6,041$30,205281,096 total(indirect: By FSV II-B, LP)
  • Exercise/Conversion

    Warrants to Purchase Series B Preferred Stock

    2018-10-227100 total(indirect: By FSV II, LP)
    Exercise: $0.12Series B Preferred Stock (710 underlying)
  • Exercise/Conversion

    Warrants to Purchase Series C-1 Preferred Stock

    2018-10-224,6900 total(indirect: By FSV II-B, LP)
    Exercise: $0.12Series C-1 Preferred Stock (4,690 underlying)
  • Conversion

    Common Stock

    2018-10-22+275,055275,055 total(indirect: By FSV II-B, LP)
  • Exercise/Conversion

    Warrants to Purchase Series B Preferred Stock

    2018-10-227,0530 total(indirect: By Fletcher Spaght Ventures II, LP)
    Exercise: $0.12Series B Preferred Stock (7,053 underlying)
  • Exercise/Conversion

    Series B Preferred Stock

    2018-10-22$0.12/sh+7,053$846347,420 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (7,053 underlying)
  • Sale

    Series B Preferred Stock

    2018-10-22$5.00/sh170$850347,250 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (170 underlying)
  • Sale

    Series B Preferred Stock

    2018-10-22$5.00/sh18$9034,968 total(indirect: By FSV II, LP)
    Common Stock (18 underlying)
  • Exercise/Conversion

    Warrants to Purchase Series B Preferred Stock

    2018-10-223,3590 total(indirect: By FSV II-B, LP)
    Exercise: $0.12Series B Preferred Stock (3,359 underlying)
  • Sale

    Series B Preferred Stock

    2018-10-22$5.00/sh81$405165,395 total(indirect: By FSV II-B, LP)
    Common Stock (81 underlying)
  • Exercise/Conversion

    Series C-1 Preferred Stock

    2018-10-22$0.12/sh+991$1194,770 total(indirect: By FSV II, LP)
    Common Stock (991 underlying)
  • Exercise/Conversion

    Series C-1 Preferred Stock

    2018-10-22$0.12/sh+4,690$56322,565 total(indirect: By FSV II-B, LP)
    Common Stock (4,690 underlying)
  • Conversion

    Series AA Preferred Stock

    2018-10-2212,0250 total(indirect: By FSV II, LP)
    Common Stock (12,025 underlying)
  • Conversion

    Series D Preferred Stock

    2018-10-2263,6880 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (63,688 underlying)
  • Conversion

    Common Stock

    2018-10-22+577,486577,486 total(indirect: By Fletcher Spaght Ventures II, LP)
  • Conversion

    Common Stock

    2018-10-22+58,15258,152 total(indirect: By FSV II, LP)
  • Exercise/Conversion

    Series B Preferred Stock

    2018-10-22$0.12/sh+710$8534,986 total(indirect: By FSV II, LP)
    Common Stock (710 underlying)
  • Exercise/Conversion

    Series B Preferred Stock

    2018-10-22$0.12/sh+3,359$403165,476 total(indirect: By FSV II-B, LP)
    Common Stock (3,359 underlying)
  • Sale

    Series C-1 Preferred Stock

    2018-10-22$5.00/sh237$1,18547,140 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (237 underlying)
  • Sale

    Series C-1 Preferred Stock

    2018-10-22$5.00/sh113$56522,452 total(indirect: By FSV II-B, LP)
    Common Stock (113 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2018-10-2247,1400 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (47,140 underlying)
  • Purchase

    Common Stock

    2018-10-22$5.00/sh+12,682$63,410590,168 total(indirect: By Fletcher Spaght Ventures II, LP)
  • Exercise/Conversion

    Warrants to Purchase Series C-1 Preferred Stock

    2018-10-229,8470 total(indirect: By Fletcher Spaght Ventures II, LP)
    Exercise: $0.12Series C-1 Preferred Stock (9,847 underlying)
  • Sale

    Series C-1 Preferred Stock

    2018-10-22$5.00/sh24$1204,746 total(indirect: By FSV II, LP)
    Common Stock (24 underlying)
  • Conversion

    Series AA Preferred Stock

    2018-10-22119,4080 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (119,408 underlying)
  • Conversion

    Series B Preferred Stock

    2018-10-22347,2500 total(indirect: By Fletcher Spaght Ventures II, LP)
    Common Stock (347,250 underlying)
  • Conversion

    Series B Preferred Stock

    2018-10-2234,9680 total(indirect: By FSV II, LP)
    Common Stock (34,968 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2018-10-2222,4520 total(indirect: By FSV II-B, LP)
    Common Stock (22,452 underlying)
  • Conversion

    Series D Preferred Stock

    2018-10-226,4130 total(indirect: By FSV II, LP)
    Common Stock (6,413 underlying)
  • Conversion

    Series B Preferred Stock

    2018-10-22165,3950 total(indirect: By FSV II-B, LP)
    Common Stock (165,395 underlying)
  • Conversion

    Series C-1 Preferred Stock

    2018-10-224,7460 total(indirect: By FSV II, LP)
    Common Stock (4,746 underlying)
  • Conversion

    Series AA Preferred Stock

    2018-10-2256,8740 total(indirect: By FSV II-B, LP)
    Common Stock (56,874 underlying)
  • Conversion

    Series D Preferred Stock

    2018-10-2230,3340 total(indirect: By FSV II-B, LP)
    Common Stock (30,334 underlying)
Footnotes (4)
  • [F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
  • [F2]FSA II, LLC is the general partner of the general partner of Fletcher Spaght Ventures II, LP and FSV II-B, LP and the manager of the general partner of FSV II, LP. The reporting person is a managing member of FSA II, LLC and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
  • [F3]Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
  • [F4]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.

Issuer

PhaseBio Pharmaceuticals Inc

CIK 0001169245

Entity typeother

Related Parties

1
  • filerCIK 0001388680

Filing Metadata

Form type
4
Filed
Oct 23, 8:00 PM ET
Accepted
Oct 24, 4:20 PM ET
Size
85.5 KB